URMC Research Network - Alok Khorana

Find People

Alok Khorana

Title	Associate Professor
Institution	School of Medicine and Dentistry
Department	Medicine
Address	University of Rochester Medical Center School of Medicine and Dentistry 601 Elmwood Ave, Box 704 Rochester NY 14642

Other Positions


Title	Associate Professor
Institution	University of Rochester Medical Center
Department	Cancer Center

Awards And Honors

2001	-	2004	James P. Wilmot Cancer Research Fellowship
2001	-	2002	Cancer Action Grant for Cancer Research
2001	-	2002	Dr. Robert Cooper Endowed Fund for Clinical Research
2001			Faculty Award for Creative Excellence
2002			Faculty Award for Creative Excellence
2005			Teacher of the Year, Wilmot Cancer Center
2007			Who's Who in America
2007			Who's Who in Science and Engineering
2007	-	2008	Internal Medicine Research Mentoring Award, Department of Medicine
2012			Patent and Family -Centered Care Award

Overview

Alok A. Khorana, M.D., is Vice-Chief, Division of Hematology/Oncology and Associate Professor of Medicine and Oncology at the James P. Wilmot Cancer Center, University of Rochester, Rochester, New York. He co-directs the cancer center's Multidisciplinary Gastrointestinal Cancer Program. His clinical and translational research focuses on predictive factors in gastrointestinal malignancies and cancer-associated thrombosis and is funded by grants from the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the V Foundation for Cancer Research. He is a Fellow of the American College of Physicians.

Dr. Khorana serves on the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Panel, ASCO Venous Thromboembolism Guidelines Panel, the ASCO Scientific Program Committee and the GI committees of the Southwest Oncology Group and American College of Surgeons Oncology Group. He has previously served as a member of the US Pharmacopoeia Oncology Expert Committee. Dr. Khorana's scientific work has been published in a variety of scientific journals including Journal of Clinical Oncology, Blood, Cancer and Archives of Internal Medicine. He has co-authored chapters in multiple textbooks including Cecil's Essentials of Medicine and DeVita's Cancer: Principles and Practice of Oncology. He is an associate editor of the journal Cancer Investigation. Dr. Khorana's fiction and creative nonfiction works have been published in the Bellevue Literary Review and Health Affairs and selected for Best American Medical Writing 2009 (Kaplan, 2009).

Selected Publications

Carrier M, Khorana AA, Zwicker JI, Lyman GH, Le Gal G, Lee AY. Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. J Thromb Haemost. 2012 Dec; 10(12):2599-601.

View in: PubMed
Khorana AA, O'Connell C, Agnelli G, Liebman HA, Lee AY. Incidental venous thromboembolism in oncology patients. J Thromb Haemost. 2012 Dec; 10(12):2602-4.

View in: PubMed
Spyropoulos AC, McGinn T, Khorana A. The use of weighted and scored risk assessment models for venous thromboembolism. Thromb Haemost. 2012 Nov 29; 108(6):1072-6.

View in: PubMed
Connolly GC, Safadjou S, Chen R, Nduaguba A, Dunne R, Khorana AA, Hezel AF. Diabetes mellitus is associated with the presence of metastatic spread at disease presentation in hepatocellular carcinoma. Cancer Invest. 2012 Dec; 30(10):698-702.

View in: PubMed
Connolly GC, Dalal M, Lin J, Khorana AA. Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer. 2012 Dec; 78(3):253-8.

View in: PubMed
Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013 Feb 1; 119(3):648-55.

View in: PubMed
Khorana AA, Spyropoulos AC, Zwicker J, Lyman GH, Francis CW. Preventing VTE in Outpatients With Cancer. Chest. 2012 Jul 1; 142(1):265-6.

View in: PubMed
Khorana AA. Embolic stroke in a patient with a patent foramen ovale and an indwelling catheter. Clin Adv Hematol Oncol. 2012 May; 10(5):337-8.

View in: PubMed
Khorana AA. Predicting and accounting for VTE in phase I cancer studies. Ann Oncol. 2012 Jun; 23(6):1373-5.

View in: PubMed
Khorana AA. PL-02 Risk assessment for cancer-associated thrombosis: What is the best approach? Thromb Res. 2012 Apr; 129 Suppl 1:S10-5.

View in: PubMed
Khorana AA. Cancer and coagulation. Am J Hematol. 2012 May; 87 Suppl 1:S82-7.

View in: PubMed
Khorana AA. Cancer-associated thrombosis: updates and controversies. Hematology Am Soc Hematol Educ Program. 2012; 2012:626-30.

View in: PubMed
Khorana AA. Risk assessment and prophylaxis for VTE in cancer patients. J Natl Compr Canc Netw. 2011 Jul 1; 9(7):789-97.

View in: PubMed
Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost. 2011 Aug; 106(2):371-8.

View in: PubMed
Liebman H, Khorana A, Kessler C. Clinical roundtable monograph. The oncologist's role in management of venous thromboembolism. Clin Adv Hematol Oncol. 2011 Jan; 9(1):suppl 1-15.

View in: PubMed
Khorana AA, Shayne M, Korones DN. Can literature enhance oncology training? A pilot humanities curriculum. J Clin Oncol. 2011 Feb 1; 29(4):468-71.

View in: PubMed
Menapace LA, Khorana AA. The role of thromboprophylaxis in cancer patients: emerging data. Curr Opin Hematol. 2010 Sep; 17(5):450-6.

View in: PubMed
Connolly GC, Khorana AA, Kuderer NM, Culakova E, Francis CW, Lyman GH. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res. 2010 Aug; 126(2):113-8.

View in: PubMed
Khorana AA. The role of the oncologist in the management of VTE. Clin Adv Hematol Oncol. 2010 Aug; 8(8):524-6.

View in: PubMed
Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010 Aug 1; 28(22):3605-10.

View in: PubMed
Khorana AA. Physician as typist. J Clin Oncol. 2010 Aug 20; 28(24):3899-900.

View in: PubMed
Singh R, Sousou T, Mohile S, Khorana AA. High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients. J Thromb Haemost. 2010 Aug; 8(8):1879-81.

View in: PubMed
Lo SS, Khorana AA, Javle M, Simon S, Kiefer G, Rajasenan K, Wang H, Hantel A, Shayne M, Hwang J, Schmotzer A, Ramanathan RK. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. Oncology. 2010; 78(2):125-9.

View in: PubMed
Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res. 2010 Apr; 125 Suppl 2:S1-7.

View in: PubMed
Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010 Jun; 125(6):490-3.

View in: PubMed
Sousou T, Khorana AA. Cancer patients and awareness of venous thromboembolism. Cancer Invest. 2010 Jan; 28(1):44-5.

View in: PubMed
Candelario GD, Francis CW, Panzer R, McAdam KS, Cockrell D, Baird T, Khorana AA. A computerized prompt for thromboprophylaxis in hospitalized cancer patients. Thromb Res. 2010 Jul; 126(1):32-4.

View in: PubMed
Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009 Oct 10; 27(29):4821-6.

View in: PubMed
Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009 Oct 10; 27(29):4839-47.

View in: PubMed
Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol. 2009 Oct 10; 27(29):4919-26.

View in: PubMed
Khorana AA. Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol. 2009 Oct; 20(10):1619-30.

View in: PubMed
Lyman GH, Khorana AA, Kuderer NM, Lee AY. Cancer and thrombosis: back to the future renewed interest in an old problem. Cancer Invest. 2009 Jun; 27(5):472-3.

View in: PubMed
Yao JL, Ryan CK, Francis CW, Kohli M, Taubman MB, Khorana AA. Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study. Cancer Invest. 2009 May; 27(4):430-4.

View in: PubMed
Sousou T, Khorana AA. New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol. 2009 Mar; 29(3):316-20.

View in: PubMed
Connolly GC, Khorana AA. Risk stratification for cancer-associated venous thromboembolism. Best Pract Res Clin Haematol. 2009 Mar; 22(1):35-47.

View in: PubMed
Sousou T, Khorana A. Identifying cancer patients at risk for venous thromboembolism. Hamostaseologie. 2009 Jan; 29(1):121-4.

View in: PubMed
Sud R, Khorana AA. Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res. 2009; 123 Suppl 4:S18-21.

View in: PubMed
Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008 Nov 24; 168(21):2377-81.

View in: PubMed
Ferro SA, Myer BS, Wolff DA, Poniewierski MS, Culakova E, Cosler LE, Scarpace SL, Khorana AA, Lyman GH. Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care. 2008 Nov; 14(11):717-25.

View in: PubMed
Khorana AA, Francis CW, Menzies KE, Wang JG, Hyrien O, Hathcock J, Mackman N, Taubman MB. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 2008 Nov; 6(11):1983-5.

View in: PubMed
Khorana AA. Disorientation. Health Aff (Millwood). 2008 Jul-Aug; 27(4):1154-9.

View in: PubMed
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 May 15; 111(10):4902-7.

View in: PubMed
Connolly GC, Chen R, Hyrien O, Mantry P, Bozorgzadeh A, Abt P, Khorana AA. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res. 2008; 122(3):299-306.

View in: PubMed
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007 Nov 15; 110(10):2339-46.

View in: PubMed
Khorana AA. The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. Oncologist. 2007 Nov; 12(11):1361-70.

View in: PubMed
Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 Dec 1; 25(34):5490-505.

View in: PubMed
Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007 Sep 1; 110(5):1149-61.

View in: PubMed
Bozorgzadeh A, Orloff M, Abt P, Tsoulfas G, Younan D, Kashyap R, Jain A, Mantry P, Maliakkal B, Khorana A, Schwartz S. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Liver Transpl. 2007 Jun; 13(6):807-13.

View in: PubMed
Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, Hostetter G, Harvey J, Taubman MB. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007 May 15; 13(10):2870-5.

View in: PubMed
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007 Mar; 5(3):632-4.

View in: PubMed
Khorana AA, Rao MV. Approaches to risk-stratifying cancer patients for venous thromboembolism. Thromb Res. 2007; 120 Suppl 2:S41-50.

View in: PubMed
Komrokji RS, Uppal NP, Khorana AA, Lyman GH, Kaplan KL, Fisher RI, Francis CW. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006 Jun; 47(6):1029-33.

View in: PubMed
Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006 Jan 20; 24(3):484-90.

View in: PubMed
Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005 Dec 15; 104(12):2822-9.

View in: PubMed
Sahni A, Khorana AA, Baggs RB, Peng H, Francis CW. FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. Blood. 2006 Jan 1; 107(1):126-31.

View in: PubMed
Khorana AA, Hu YC, Ryan CK, Komorowski RA, Hostetter G, Ahrendt SA. Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer. J Gastrointest Surg. 2005 Sep-Oct; 9(7):903-11.

View in: PubMed
Khorana AA. Concordance: how does a physician who is neither black nor white decide when race is a factor? Health Aff (Millwood). 2005 Mar-Apr; 24(2):511-5.

View in: PubMed
Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol. 2004 Nov; 5(11):655-63.

View in: PubMed
Shunyakov L, Ryan CK, Sahasrabudhe DM, Khorana AA. The influence of host response on colorectal cancer prognosis. Clin Colorectal Cancer. 2004 May; 4(1):38-45.

View in: PubMed
Khorana AA. Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemost. 2003 Dec; 1(12):2463-5.

View in: PubMed
Khorana A. At the end of A day. A young doctor considers an end-of-life decision and the love that informs it. Health Aff (Millwood). 2003 Nov-Dec; 22(6):239-43.

View in: PubMed
Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol. 2003 Nov 1; 23(11):2110-5.

View in: PubMed
Khorana AA, Rosenblatt JD, Sahasrabudhe DM, Evans T, Ladrigan M, Marquis D, Rosell K, Whiteside T, Phillippe S, Acres B, Slos P, Squiban P, Ross M, Kendra K. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther. 2003 Apr; 10(4):251-9.

View in: PubMed
Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer. 2003 Feb 15; 97(4):960-8.

View in: PubMed
Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma. 2001 Mar; 41(1-2):77-87.

View in: PubMed
Khorana AA, Rosenblatt JD, Young FM. Immunopathogenesis of HIV and HTLV-1 infection: mechanisms for lymphomagenesis. Cancer Treat Res. 2001; 104:19-74.

View in: PubMed